IMMY20022/CAEL101-301/Frank Passero
Basic Study Information
Purpose:
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins
misfold and create free light chains that cannot be broken down. These free light
chains bind together to form amyloid fibrils that build up in the extracellular space
of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive
tract.
The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody
that removes AL amyloid deposits from tissues and organs, improves overall survival
and it is safe and well tolerated in patients with stage IIIb AL amyloidosis.
Location: University of Rochester- Wilmot Cancer Center
Lead Researcher (Principal Investigator)
Lead Researcher:
Frank Passero
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search